A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE II, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP,46 WEEKS DOSE-FINDING STUDY OF BI 456906 ADMINISTERED ONCE WEEKLY SUBCUTANEOUSLY COMPARED WITH PLACEBO IN PATIENTS WITH OBESITY OR OVERWEIGHT

Intervention/treatment:
BI 456906
Medical condition:
OBESITY
Protocol code:
1404-0036
Control number:
246577
Status:
Closed
Approved:
December 18, 2020
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT04667377
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Boehringer Ingelheim, Call Centre
Organization
Boehringer Ingelheim
Phone:
1-800-243-0127
Sponsor
BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Locations

Ontario

Bluewater Clinical Research
Sarnia, Ontario, N7T 4X3
Canadian Phase Onward Inc.
Toronto, Ontario, M3J 0K2
Joanne F Liutkus Medicine Professional Corporation
Cambridge, Ontario, N3H 4L5
LMC Clinical Research Inc. (Bayview)
Toronto, Ontario, M4G 3E8

Quebec

Recherche GCP Research
Montreal, Quebec, H1M 1B1

Results

See the results from the trial NCT04667377. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?